Influence of erythropoietin treatment on glucose tolerance, insulin, glucagon, gastrin and pancreatic polypeptide secretion in haemodialyzed patients with end-stage renal failure.
Kokot
F
F
Department of Nephrology, Silesian School of Medicine, Katowice, Poland.
Wiecek
A
A
Grzeszczak
W
W
Klin
M
M
Zukowska-Szczechowska
E
E
D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D004921:Erythropoietin / Q000627:therapeutic use*; D005755:Gastrins / Q000378:metabolism; D005768:Gastrointestinal Hormones / Q000378:metabolism*; D005934:Glucagon / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D006435:Renal Dialysis
D001786:Blood Glucose; D005755:Gastrins; D005768:Gastrointestinal Hormones; D007328:Insulin; D004921:Erythropoietin; D010191:Pancreatic Polypeptide; D005934:Glucagon